Build your own keyword analysis with our tools
SEO Report
Server Infos

HTML Analysis

Page Status


Highlighted Content

Aim at Melanoma - Homepage


AIM is a cancer research organization committed to increasing support for melanoma research; promoting prevention and education; and providing comprehensive resources for patients, survivors, and caregivers.


Melanoma, Malinoma, Melinoma, Malenoma, Melenoma, Mallinoma, Mellinoma, Mallanoma, Mellanoma, Mallenoma, Mellenoma, Melanoma Cancer, Malinoma Cancer, Melinoma Cancer, Malenoma Cancer, Melenoma Cancer, Mallinoma Cancer, Mellinoma Cancer, Mallanoma Cancer, Mellanoma Cancer, Mallenoma Cancer, Mellenoma Cancer, Melanoma Cancer Foundation, Cancer Foundation, Cancer Foundatoin, Research Foundation, Research Foundatoin, Reasearch Foundation, Reasearch Foundatoin, Cancer, Skin Cancer, Basil Cell Carcinoma, Basel Cell Carcinoma


AIM At Melanoma
Click Stage for treatment information
Click Stage to read stories by individuals
Click Stage for questions to ask doctors


Breaking News
Melanoma Discussion
Patient & Caregiver Symposiums
Participate in a Fundraiser
Make a Donation
Make a Special Donation


The Right Information
Inspiration for Action
Committed to a CURE
GSK Files Melanoma Drug Combination Early in Race to Market
Surgeons Report Melanoma Recurs After 10 Years in More Than 6 Percent of Patients
Concurrent Nivolumab, Ipilimumab Induced Rapid, Deep, Durable Responses in Advanced Melanoma
Targeted Duo Boosts OS in Melanoma
Merck: Drug Shrinks Tumors in Melanoma Patients
Bristol Drug Shrinks Melanoma in 31 Percent of Trial Patients
Amgen Melanoma Drug Improved Survival By 21 Pct in Interim Look
UPDATE 1-FDA Approves Two Glaxo Melanoma Drugs
Roche Immunotherapy Shows Response Over Range of Cancers



Text Analysis

Cloud of Keywords from all content
High relevance


Medium relevance

drug learn stage patients 06 aim

Low relevance

learn stage patients 06 aim 0 stage melanoma 06 1 stage 2 stage percent shrinks 3 stage

Very Low relevance
0 stage melanoma 06 1 stage 2 stage percent shrinks 3 stage interim privacy pct survival improved look 05 2013 update drugs 05 2013 roche glaxo approves 1-fda 2013 amgen trial boosts 2013 merck duo 2013 targeted ruby powered sponsors 2013 bristol policy map tumors immunotherapy response country participate symposiums educational hosts fundraiser make donation make services matching trials donation clinical symposiums aim foundation approved drugs melanoma fda cancers range advanced terms caregiver discussion patient rights reserved copyright ipilimumab developing treatments latest cure more committed legislation more stages treatment information stage trials click stories clinical melanoma survivor difference involved nurseoncall contact navigation skip homepage glossary join action ways more inspiration information everything facebook 4 click stories report recurs 2013 surgeons market 06 race years 2013 concurrent deep durable rapid induced nivolumab combination files 2 survivors 3 survivors 1 survivors 0 survivors individuals survivors 4 click questions 2013 gsk news 07 news breaking doctors stage responses

Highlighted Content Analysis

Cloud of Keywords from all content
High relevance


Medium relevance

patients drug stage click aim

Low relevance

stage click aim cancer shrinks donation committed percent

Very Low relevance
cancer shrinks donation committed percent immunotherapy roche response malinoma melinoma malenoma drugs cancers range melenoma approves amgen improved trial bristol tumors survival pct mallinoma 1-fda update interim glaxo mallenoma cancer foundatoin research foundation cancer foundation melanoma cancer foundation mellenoma cancer research foundatoin reasearch foundation basel cell carcinoma basil cell carcinoma skin cancer reasearch foundatoin mallenoma cancer mellanoma cancer melanoma cancer malinoma cancer mellenoma mellanoma mallanoma melinoma cancer malenoma cancer mallanoma cancer mellinoma cancer mallinoma cancer melenoma cancer mellinoma responses questions doctors individuals stories treatment breaking news symposiums caregiver patient discussion caregivers survivors support increasing organization homepage promoting prevention resources comprehensive providing education participate fundraiser induced rapid ipilimumab nivolumab concurrent deep durable boosts duo targeted advanced years recurs gsk cure action inspiration files combination report surgeons market race merck